Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Jounce Therapeutics Inc (JNCE)  
$1.88 0.00 (0.00%) as of 4:30 Wed 5/3


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 51,230,000
Market Cap: 96.31(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.88 - $1.88
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 85,987
Total Buy Value $0 $0 $0 $85,958
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 2
Total Shares Sold 0 0 0 124,313
Total Sell Value $0 $0 $0 $167,105
Total People Sold 0 0 0 4
Total Sell Transactions 0 0 0 9
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 158
  Page 7 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Karsen Perry A Director   –       •      –    2017-02-01 4 B $16.00 $80,000 D/D 5,000 5,000 2.39     -
   Higgons John Duncan Director   –       •      –    2017-02-01 4 B $16.00 $107,200 D/D 6,700 27,025 2.39     -
   Hadley Harbor Master Investors (cayman) L.p. 10% Owner   –       –       •   2017-02-01 4 A $0.00 $0 D/D 719,476 719,476     -
   Celgene Corp /de/ 10% Owner   –       –       •   2017-02-01 4 B $16.00 $10,000,000 D/D 625,000 3,456,463 2.45     -
   Celgene Corp /de/ 10% Owner   –       –       •   2017-02-01 4 A $0.00 $0 D/D 2,831,463 2,831,463     -
   Starr Kevin P 10% Owner   –       –       •   2017-01-26 3 IO $0.00 $0 D/D 0 542,005     -
   Drapkin Kimberlee C CFO and TreasurerOfficer   •       –      –    2017-01-26 3 IO $0.00 $0 D/D 0 6,775     -
   Tepper Robert I Director   –       •       •   2017-01-26 3 IO $0.00 $0 I/I 0 542,005     -

  158 Records found
  1  2  3  4  5  6  7    
  Page 7 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed